These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35553629)

  • 1. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
    Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA
    Front Immunol; 2022; 13():926318. PubMed ID: 35990701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
    Louapre C; Belin L; Marot S; Hippolyte A; Januel E; Ibrahim M; Jeantin L; Zafilaza K; Malet I; Charbonnier-Beaupel F; Rosenzwajg M; Soulié C; Marcelin AG; Pourcher V
    Eur J Neurol; 2023 Sep; 30(9):2781-2792. PubMed ID: 37310391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
    Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
    Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    Verstegen NJM; Hagen RR; Kreher C; Kuijper LH; Dijssel JVD; Ashhurst T; Kummer LYL; Palomares Cabeza V; Steenhuis M; Duurland MC; Jongh R; Schoot CEV; Konijn VAL; Mul E; Kedzierska K; van Dam KPJ; Stalman EW; Boekel L; Wolbink G; Tas SW; Killestein J; Rispens T; Wieske L; Kuijpers TW; Eftimov F; van Kempen ZLE; van Ham SM; Ten Brinke A; van de Sandt CE;
    J Neurol Neurosurg Psychiatry; 2024 Aug; 95(9):855-864. PubMed ID: 38548324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
    Baker D; Roberts CAK; Pryce G; Kang AS; Marta M; Reyes S; Schmierer K; Giovannoni G; Amor S
    Clin Exp Immunol; 2020 Nov; 202(2):149-161. PubMed ID: 32671831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccine Response in People with Multiple Sclerosis.
    Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
    Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
    Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
    Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy.
    Bazzi SA; Maguire C; Holay N; Geltman J; Hurley K; DiPasquale C; Abigania M; Olson E; Ehrlich LIR; Triplett TA; Melamed E
    Mult Scler Relat Disord; 2022 Dec; 68():104195. PubMed ID: 36223705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
    Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
    Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
    Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
    Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
    Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
    Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R
    Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
    Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
    Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Georgieva ZG; Dӧffinger R; Kumararatne D; Coles AJ; McCarthy C
    Mult Scler; 2022 Jun; 28(7):1126-1130. PubMed ID: 34595965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
    Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.